Sex hormones, metabolic syndrome and kidney

Current Topics in Medicinal Chemistry

Volumn 11, Issue 13, 2011, Pages 1694-1705

  Perez Torres I ^a   Guarner, V ^a   El Hafidi, M ^a   Banos G ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Kidney; Metabolic syndrome; Sex hormones

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANGIOTENSIN II; ANGIOTENSINOGEN; CALCIUM CHANNEL T TYPE; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FIBRONECTIN; FLUTAMIDE; G PROTEIN COUPLED RECEPTOR 30; ISOPROSTANE DERIVATIVE; LAMININ; LIPOXYGENASE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROGESTERONE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; SCLEROPROTEIN; TESTOSTERONE; TRANSFORMING GROWTH FACTOR; UNINDEXED DRUG;

ARACHIDONIC ACID METABOLISM; ARTICLE; BOWMAN CAPSULE; CELL MEMBRANE; CREATININE CLEARANCE; DIURESIS; ENZYME ACTIVITY; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; GENETIC PREDISPOSITION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART PROTECTION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYDROXYLATION; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY TUBULE DAMAGE; METABOLIC SYNDROME X; METABOLISM; NONHUMAN; POSTMENOPAUSE; PROTEIN VARIANT; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; SIGNAL TRANSDUCTION; SODIUM EXCRETION; SODIUM METABOLISM; SURVIVAL; TESTOSTERONE BLOOD LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

GONADAL STEROID HORMONES; HUMANS; KIDNEY; KIDNEY DISEASES; METABOLIC SYNDROME X;

EID: 79959929005     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796117577     Document Type: Article

References (159)

1. Sui, Y.; Zhao, H. L.; Fan, R. R.; Guan, J.; He, L.; Lee, H. M.; Chan, J. C.; Tong, P. C. Renin-angiotensin system activation in re nal adipogenesis. Am. J. Physiol. Renal. Physiol., 2010, 298, F391-F400.
2. Anderson, S.; Brenner, M. The role of intraglomerular pressure in the initiation and progression of renal disease. J. Hypertens., 1986, 4, S236-S238.
3. Kaplan, N. Microalbuminuria: A risk factor for vascular and renal complications of hypertension. Am. J. Med., 1992, 92, 85-125.
4. Crimi, E.; Ignarro, J.; Napoli, C. Microcirculation and oxidative stress. Free. Radic. Res., 2007, 41, 1364-1375.
5. Gryglewski, J.; Botting, M.; Vane, R. Mediators produced by the endothelial cell. Hypertension, 1988, 12, 530-548.
6. Kublickiene, K.; Luksha, L. Gender and the endothelium. Pharmacol. Rep., 2008, 60, 49-60.
7. Villar, I. C.; Francis, S.; Webb, A.; Hobbs, A. J.; Ahluwalia, A. Novel aspects of endothelium-dependent regulation of vascular tone. Kidney. Int., 2006, 70, 840-853.
8. Cozma, A.; Orǎşan, O.; Sâmpelean, D.; Fodor, A.; Vlad, C.; Negrean, V.; Rednic, N.; Zdrenghea, D. Endothelial dysfunction in metabolic syndrome. Rom. J. Intern. Med., 2009, 47, 133-140.
9. Bantle, J. P. Dietary fructose and metabolic syndrome and diabetes. J. Nutr., 2009, 139, 1263S-1268S.
10. Pérez, T. I.; Roque, P.; El Hafidi, M.; Diaz, D. E.; Baños, G. Association of renal damage and oxidative stress in a rat model of metabolic syndrome. Influence of gender. Free. Radic. Res., 2009, 43, 761-771.
11. Baños, G.; El Hafidi, M. Models of experimental hypertension. In New Research: Hypertension. Benhagen, E. F.; Eds.; Nova Science Publishers Inc: New York, 2005; pp 1-46.
12. Locatelli, F.; Pozzoni, P.; Del Vecchio, L. Renal manifestations in the metabolic syndrome J. Am. Soc. Nephrol., 2006, 17, S81-S85.
13. Virdis, A.; Ghiadoni, L.; Sudano, I.; Buralli, S.; Salvetti, G.; Taddei, S.; Salvetti, A. Endothelial function in hypertension: role of gender. J. Hypertens. Suppl., 2002, 20, S11-S16.
14. Castelli, P. Cardiovascular disease in women. Am. J. Obstet. Gynecol., 1998, 6, 1553-1560.
15. Colditz, A.; Willet, C.; Stampfner, J. Menopause and the risk of coronary heart disease in women. N. Engl. J. Med., 1987, 316, 1105-1110.
16. Sullivan, M.; Van der Zwagg, R.; Hughes, P. Estrogen replacement and coronary artery disease. Arch. Int. Med., 1990, 150, 2557-2562.
17. Adams, F.; Sueta, A.; Gheorghiade, M.; O'Connor, M.; Schwartz, A.; Koch, G.; Uretsky, B.; Swedberg, K.; McKenna, W.; Soler, S. J.; Califf, M. Gender differences in survival in advanced heart failure. Insights from the first study. Circulation, 1999, 14, 1816-1821.
18. Miller, V. M. Gender and vascular reactivity. Lupus, 1999, 8, 409-415.
19. Heldring, N.; Pike, A.; Andersson, S.; Matthews, J.; Cheng, G.; Hartman, J.; Tujague, M.; Ström, A.; Treuter, E.; Warner, M.; Gustafsson, J. A. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev., 2007, 87, 905-931.
20. Kos, M.; Denger, S.; Reid, G.; Gannon, F. Upstream open reading frames regulate the translation of the multiple mRNA variants of the estrogen receptor alpha. J. Biol. Chem., 2002, 277, 37131-37138.
21. Campbell, T. M.; Lynch, I. J.; Bhardwaj, B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer. Res., 2001, 6, 632-640.
22. Filice, E.; Recchia, A.; G.; Pellegrino, D.; Angelone, T.; Maggiolini, M.; Cerra, M. C. A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17betaestradiol in the male rat. J. Physiol. Pharmacol., 2009, 60, 3-10.
23. Herynk, M. H.; Fuqua, S. A. Estrogen receptor mutations in human disease. Endocr. Rev., 2004, 25, 869-898.
24. Stirone, C.; Duckles, S. P.; Krause, D. N. Multiple forms of estrogen receptor-alpha in cerebral blood vessels: regulation by estrogen. Am. J. Physiol. Endocrinol. Metab., 2003, 284, E184-E192.
25. Pendaries, C.; Darblade, B.; Rochaix, P.; Krust, A.; Chambon, P.; Korach, K. S.; Bayard, F.; Arnal, J. F. The AF-1 activationfunction of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc. Natl. Acad. Sci., 2002, 99, 2205-2210.
26. May, M.; Couse, F. J.; Korach, S. K. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem., 2001, 276, 36869-36872.
27. Russell, S. K.; Haynes, P. M.; Clerisme, E.; Bemder, R. J. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc. Natl. Acad. Sci., 2000, 97, 5930-5935.
28. Reckelhoff, J. F.; Zhang, H.; Srivastava, K. Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension, 2000, 35, 480-483.
29. Reckelhoff, J. F.; Granger, J. P. Role of androgens in mediating hypertension and renal injury. Clin. Exp. Pharmacol. Physiol., 1999, 26, 127-131.
30. Reckelhoff, J. F. Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension, 2005, 45, 170-174.
31. Potier, M.; Karl, M.; Zheng, F.; Elliot, S. J.; Striker, G. E.; Striker, L. J. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am. J. Pathol., 2002, 160, 1877-1885.
32. Ichihara, A.; Sakoda, M.; Kurauchi, M. A.; Kaneshiro, Y.; Itoh, H. Renin, prorenin and the kidney: a new chapter in an old saga. J. Nephrol., 2009, 22, 306-311.
33. Engeli, S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contrib. Nephrol., 2006, 15, 122-134.
34. Dendorfer, A.; Dominiak, P.; Schunkert, H. ACE inhibitors and angiotensin II receptor antagonists. Hand. Exp. Pharmacol., 2005, 170, 407-442.
35. Seltzer, A.; Pinto, J.; Viglione, P.; Correa, F.; Libertun, C.; Tsutsumi, K.; Steele, M.; Saavedra, J. Estrogens regulate ACE and angiotensin receptors in female rat anterior pituitary. Neuroendocrinology, 1992, 55, 460-467.
36. Brosnihan, K. B.; Weddle, D.; Anthony, M. S.; Heise, C.; Li, P.; Ferrario, C. M. Effectes of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. J. Hypertens, 1997, 15, 719-726.
37. Rogers, J. L.; Mitchell, A. R.; Maric, C.; Sandberg, K.; Myers, A.; Mulroney, S. E. Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292, R794-R799.
38. Nickenig, G.; Bäumer, A. T.; Grohè, C.; Kahlert, S.; Strehlow, K.; Rosenkranz, S.; Stäblein, A.; Beckers, F.; Smits, J. F.; Daemen, M. J.; Vetter, H.; Böhm, M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation, 1998, 97, 2197-2201.
39. Prime, D. D.; Brosnihan, K. B.; Herrington, D. M. Effects of hormone therapy on blood pressure and the renin-angiotensin system in postmenopausal women. Minerva. Cardioangiol., 2007, 55, 477-485.
40. Raizada, M. K.; Ferreira, A. J. ACE2: a new target for cardiovascular disease therapeutics. J. Cardiovasc. Pharmacol., 2007, 50, 112-119.
41. Ye, M.; Wysocki, J.; William, J.; Soler, M.; J.; Cokic, I.; Batlle, D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol., 2006, 17, 3067-3075.
42. Wong, D. W.; Oudit, G. Y.; Reich, H.; Kassiri, Z.; Zhou, J.; Liu, Q. C.; Backx, P. H.; Penninger, J. M.; Herzenberg, A. M.; Scholey, J. W. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am. J. Pathol., 2007, 171, 438-451.
43. Ji, H.; Menini, S.; Zheng, W.; Pesce, C.; Wu, X.; Sandberg, K. Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Exp. Physiol., 2008, 93, 648-657.
44. Kienitz, T.; Quinkler, M. Testosterone and blood pressure regulation. Kidney. Blood. Press., 2008, 31, 71-79.
45. Quan, A.; Chakravarty, S.; Chen, J. K.; Chen, J. C.; Loleh, S.; Saini, N.; Harris, R. C.; Capdevila, J.; Quigley, R. Androgens augment proximal tubule transport. Am. J. Physiol. Renal. Physiol., 2004, 287, F452-F459.
46. Chen, Y. F.; Naftilan, A. J.; Oparil, S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension, 1992, 19, 456-463.
47. Song, J.; Kost, C.; Martin, D. androgens potentiate renal vascular responses to angitensin II via amplification of the Rho kinase signaling pathway. Cardiovasc. Res., 2006, 72, 456-463.
48. Yanes, L. L.; Sartori, J. C.; Reckelhoff, J. F. Sex steroids and renal disease: lessons from animal studies. Hypertension, 2008, 51, 976-981.
49. Ritz, E.; Orth, S. R.; Strzelczyk, P. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J. Hypertens. Suppl., 1997, 15, S21-S26.
50. Zatz, R.; Meyer, T.; Rennket, H.; Brenner, B. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc. Natl. Acad. Sci., 1985, 82, 5963-5967.
51. Zewde, T.; Mattson, L. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension, 2004, 44, 424-428.
52. Dubois, R.; Abramson, S.; Crofford, L.; Gupta, R.; Simon, L.; Van de Putte, L., Lipsky, P. Cyclooxygenase in biology and disease. FASEB. J., 1998, 12, 1063-1073.
53. Matsunaga, A.; Kawamoto, M.; Shiraishi, S.; Yasuda, T.; Kajiyama, S.; Kurita, S.; Yuge, O. Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocininduced mechanical hyperalgesia in rats. Eur. J. Pharmacol., 2007, 554, 12-7.
54. Cheng, H.; Harris, R. Cyclooxygenases, the kidney, and hypertension. Hypertension, 2004, 43, 525-530.
55. Harris, R. C.; McKanna, J. A.; Akai, Y.; Jacobson, H. R.; Dubois, R. N.; Breyer, M. D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest., 1994, 94, 2504-2510.
56. Yamada, M.; Omata, K.; Abe, F.; Ito, S.; Abe, K. Changes in prostacyclin, thromboxane A2 and F2-isoprostanes, and influence of eicosapentaenoic acid and antiplatelet agents in patients with hypertension and hyperlipidemia. Immunopharmacology, 1999, 44, 193-198.
57. Marnett, L.; Rowlinson, S.; Goodwin, D.; Kalgutkar, A.; Lanzo, C. Arachidonic acid oxygenation by COX-1 and COX-2. J. Biol. Chem., 1999, 274, 22903-22906.
58. Escalante, B.; McGiff, J.; Oyekan, A. Role of cytochrome p-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am. J. Physiol. Renal. Physiol., 2002, 282, F144-F150.
59. Minuz, P.; Jiang, H.; Fava, C.; Turolo, L.; Tacconelli, S.; Ricci, M.; Patrignani, P.; Morganti, A.; Lechi, A.; McGiff, J. C. Altered release of cytochrome p-450 metabolites of arachidonic acid in renovascular disease. Hypertension, 2008, 5, 1379-1385.
60. Pomposiello, S.; Quilley, J.; Carroll, M.; Falck, J.; McGiff, J. 5,6-Epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR. Hypertension, 2003, 42, 548-554.
61. Ajayi, A.; A.; Ogungbade, G. O.; Okorodudu, A. O. Sex hormone regulation of systemic endothelial and renal microvascular reactivity in type-2 diabetes: studies in gonadectomized and shamoperated Zucker diabetic rats. Eur. J. Clin. Invest., 2004, 34, 349-357.
62. Vázquez, C. B.; López, P.; Talamás, R. P.; Escalante, B. Increased renal vasoconstriction and gene expression of cyclooxygenase-1 in renovascular hypertension. J. Cardiovasc. Pharmacol., 2000, 36, 577-583.
63. Jun, S. S.; Chen, Z.; Pace, M. C.; Shaul, P. W. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. J. Clin. Invest., 1998, 102, 176-183.
64. Akarasereenont, P.; Techatraisak, K.; Thaworn, A.; Chotewuttakorn, S. The induction of cyclooxygenase-2 by 17beta-estradiol in endothelial cells is mediated through protein kinase C. Inflamm. Res., 2000, 49, 460-465.
65. Pérez, T. I.; El Hafidi, M.; Pavón, N.; Infante, O.; Avila-Casado. C.; Baños, G. Effect of gonadectomy on the metabolism of arachidonic acid in isolated kidney of a rat model of metabolic syndrome. Metabolism., 2010, 59, 414-423.
66. Hiroaki, K.; Motoyama, T.; Kugiyama, K. Gender difference in improvement of endothelium dependent vasodilation after estrogen supplementation. J. Am. Coll. Cardiol., 1997, 30, 914-919.
67. Okumura, M.; Imanishi, M.; Yamashita, T.; Yamamura, Y.; Kim, S.; Iwao, H.; Tanaka, S.; Fujii, S. Renal production of thromboxane and prostaglandins in a rat model of type 2 diabetes. Life. Sci., 2000, 66, 371-377.
68. Park, K.; Kim, J.; Ahn, Y.; Bonventre, A.; Bonventre, J. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J. Biol. Chem., 2004, 279, 52282-52292.
69. Galipeau, D.; Arikawa, E.; Sekirov, I.; McNeill, J. Chronic thromboxane synthase inhibition prevents fructose-induced hypertension. Hypertension, 2001. 38, 872-876.
70. Dey, A.; Williams, R.; Pollock, D.; Stepp, D.; Newman, J.; Hammock, B.; Imig, J. Altered kidney CYP2 and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obesity. Res., 2004, 12, 1278-1289.
71. Wu, F.; Eckardstein, A. androgens and coronary artery disease. Endocr. Rev., 2003, 24, 183-217.
72. Orshal, J. M.; Khalil, R. A. Gender, sex hormones, and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2004, 286, R233-R249.
73. Silbiger, S.; Lei, J.; Neugarten, J. Estradiol suppresses type I collagen synthesis in mesangial cells via activation of activator protein-1. Kidney. Int., 1999, 55, 1268-1276.
74. Caughey, G.; Cleland, C.; Penglis, P.; Gamble, J.; James, M. Roles of cyclooxygenase COX-1 and COX-2 in prostanoid production by human endothelial cells: selective upregulation of prostacyclin synthesis by COX-2. J. Immunol., 2001, 167, 2831-2838.
75. Fortepiani, L.; Yanes, L.; Zhang, H.; Racusen, L.; Reckelhoff, J. Role of androgens in mediating renal injury in aging SHR. Hypertension, 2003, 42, 952-955.
76. Sullivan, J.; Sasser, J.; Pollock, D.; Pollock, J. Sexual dimorphism in renal production of prostanoids in spontaneously hypertensive rats. Hypertension, 2005, 45, 406-411.
77. Baber, R.; Deng, W.; Rodriguez, J.; Master, G.; Bivalacqua, J.; Hyman, L.; Philip, J.; Kadowitz, J. Vasoactive prostanoids are generated from arachidonic acid by COX-1 and COX-2 in the mouse. Am. J. Physiol. Heart. Circ. Physiol., 2005, 289, H1476-H1487.
78. Sacerdoti, D.; Escalante, B.; Abraham, N.; McGiff J, Levere, R.; Schwartzman, M. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science, 1989, 243, 388-390.
79. Lee, S. J.; Landon, C. S.; Nazian, S. J.; Dietz, J. R. Cytochrome P-450 metabolites in endothelin-stimulated cardiac hormone secretion. Am. J. Physiol. Regul. Integr. Comp. Physiol.,2004, 286, R888-R893.
80. McGiff, J. C.; Quilley, J. 20-HETE and the kidney: resolution of old problems and new beginnings. Am. J. Physiol., 1999, 277, R607-R623.
81. Zeldin, D. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem., 2001, 276, 36059-36062.
82. Ito, O.; Alonso, G. M.; Hopp, K.; Roman, R. Localization of cytochrome P-450 4A isoforms along the rat nephron. Am. J. Physiol., 1998, 274, F395-F404.
83. Imig, J.; Deichmann, P. Afferent arteriolar responses to ANG II involve activation of PLA2 and modulation by lipoxygenase and P-450 pathways. Am. J. Physiol., 1997, 273, F274-F282.
84. Oyekan, A.; McGiff, J. Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome P450-derived arachidonate metabolites. Br. J. Pharmacol., 1998, 25, 1065-1073.
85. Perico, N.; Cornejo, R.; Malanchini, B.; Ladny, J.; Remuzzi, G. Endothelin induces diuresis and natriuresis in the rat by acting on proximal tubular cells through a mechanism mediated by lipoxygenase products. J. Am. Soc. Nephrol., 1991, 2, 57-69.
86. Makita, K. K.; Takahashi, A.; Karara, H.; Jacobson, J.; Falck, R.; Capdevilla, J. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induced hypertension in rats fed a high salt diet. J. Clin. Invest., 1994, 94, 2414-2420.
87. Imig, J. D. Eicosanoid regulation of the ranal vasculature. Am. J. Physiol. Renal. Physiol., 2002, 279, F965-F981.
88. Holla, V. R.; Adas, F.; Imig, J. D.; Zhao, X.; Price, E.; Olsen, N.; Kovacs, W. J.; Magnuson, M. A.; Keeney, D. S.; Breyer, M. D.; Falck, J. R.; Waterman, M. R.; Capdevila, J. H. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc. Natl. Acad. Sci. USA, 2001, 98, 5211-5216.
89. Singh, H.; Schwartzman, M. L. Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol. Rep., 2008, 60, 29-37.
90. Singh, H.; Cheng, J.; Deng, H.; Kemp, R.; Ishizuka, T.; Nasjletti, A.; Schwartzman, M.; L. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension, 2007, 50, 123-129.
91. Zhou, Y.; Lin, S.; Chang, H. H.; Du, J.; Dong, Z.; Dorrance, A. M.; Brands, M. W.; Wang, M. H. Gender differences of renal CYP derived eicosanoid synthesis in rats fed a high-fat diet. Am. J. Hypertens., 2005, 18, 530-537.
92. Ishizuka, T.; Ito, O.; Omata, K.; Ito, S. Role of androgens in the renal production of 20-hydroxyeicosatetraenoic acid in spontaneously hypertensive rats. Nippon. Jinzo. Gakkai. Shi., 2004, 46, 685-692.
93. Tsai, I. J.; Beilin, L. J.; Puddey, I. B.; Croft, K. D.; Barden, A. Impaired ex vivo leukotriene B4 production characterizes the metabolic syndrome and is improved after weight reduction. J. Clin. Endocrinol. Metab., 2007, 92, 4747-4752.
94. Imig, J. D. Eicosanoids and renal vascular function in diseases. Clin. Sci., 2006, 111, 21-34.
95. Kang, S.; W.; Natarajan, R.; Shahed, A.; Nast, C. C.; La Page, J.; Mundel, P.; Kashtan, C.; Adler, S. G. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J. Am. Soc. Nephrol., 2003, 14, 3178-3187.
96. Kang, S. W.; Adler, S. G.; Nast, C. C.; La Page, J.; Gu, J. L.; Nadler, J. L.; Natarajan, R. 12-lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney. Int., 2001, 59, 1354-1362.
97. Hao, C. M.; Breyer, M. D. Roles of lipid mediators in kidney injury. Semin. Nephrol., 2007, 27, 338-351.
98. Katoh, T.; Takahashi, K.; DeBoer, D. K.; Serhan, C. N.; Badr, K. F. Renal hemodynamic actions of lipoxins in rats: a comparative physiological study. Am. J. Physiol., 1992, 263, F436-F442.
99. Pergola, C.; Dodt, G.; Rossi, A.; Neunhoeffer, E.; Lawrenz, B.; Northoff, H.; Samuelsson, B.; Rådmark, O.; Sautebin, L.; Werz, O. ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc. Natl. Acad. Sci. USA, 2008, 105, 19881-19886.
100. Helgadottir, A.; Manolescu, A.; Thorleifsson, G.; Gretarsdottir, S.; Jonsdottir, H.; Thorsteinsdottir, U.; Samani, N. J.; Gudmundsson, G.; Grant, S. F.; Thorgeirsson, G.; Sveinbjornsdottir, S.; Valdimarsson, E. M.; Matthiasson, S. E.; Johannsson, H.; Gudmundsdottir, O.; Gurney, M.; E.; Sainz, J.; Thorhallsdottir, M.; Andresdottir, M.; Frigge, M. L.; Topol, E. J.; Kong, A.; Gudnason, V.; Hakonarson, H.; Gulcher, J. R.; Stefansson, K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet., 2004, 36, 233-239.
101. McManus, L. M.; Bloodworth, R. C.; Prihoda, T. J.; Blodgett, J. L.; Pinckard, R. N. Agonist-dependent failure of neutrophil function in diabetes correlates with extent of hyperglycemia. J. Leukoc. Biol., 2001, 70, 395-404.
102. Kamata, K.; Hosokawa, M.; Matsumoto, T.; Kobayashi, T. Altered arachidonic acid-mediated responses in the perfused kidney of the streptozotocin-induced diabetic rat. J. Smooth. Muscle. Res., 2006, 42, 171-187.
103. Gao, L.; Zackert, W. E.; Hasford, J. J.; Danekis, M. E.; Milne, G. L.; Remmert, C.; Reese, J.; Yin, H.; Tai, H. H.; Dey, S. K.; Porter, N. A.; Morrow, J. D. Formation of prostaglandins E2 and D2 via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of cyclooxygenase. J. Biol. Chem., 2003, 278, 28479-28489.
104. Takahashi, K.; Nammour, T. M.; Fukunaga, M.; Ebert, J.; Morrow, J. D.; Roberts, L. J.; Hoover, R. L.; Badr, K. F. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. J. Clin. Invest., 1992, 90, 136-141.
105. Yura, T.; Fukunaga, M.; Khan, R.; Nassar, G. N.; Badr, K. F.; Montero, A. Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney. Int., 1999, 56, 471-478.
106. Liu, T. Z.; Stern, A.; Morrow, J. D. The isoprostanes: unique bioactive products of lipid peroxidation. An. overview. J. Biomed. Sci., 1998, 5, 415-420.
107. Kienitz, T.; Quinkler, M. Testosterone and blood pressure regulation. Kidney. Blood. Press. Res., 2008, 31, 71-79.
108. Reckelhoff, J. F.; Yanes, L. L.; Iliescu, R.; Fortepiani, L. A.; Granger, J. P. Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease. Am. J. Physiol. Renal. Physiol., 2005, 289, F941-F948.
109. Sartori, J. C.; Iliescu, R.; Yanes, L. L.; Dorsett, M. W.; Reckelhoff, J. F. Sex differences in the pressor response to angiotensin II when the endogenous renin-angiotensin system is blocked. Hypertension, 2008, 51, 1170-1176.
110. Reckelhoff, J. F.; Zhang, H.; Srivastava, K.; Roberts, L. J.; Morrow, J. D.; Romero, J. C. Subpressor doses of angiotensin II increase plasma F(2)-isoprostanes in rats. Hypertension, 2000, 35, 476-479.
111. Sartori, J. C.; Iliescu, R.; Fortepiani, L. A.; Yanes, L. L.; Reckelhoff, J. F. Sex differences in oxidative stress and the impact on blood pressure control and cardiovascular disease. Clin. Exp. Pharmacol. Physiol., 2007, 34, 938-945.
112. Sullivan, J. C.; Pardieck, J. L.; Hyndman, K. A.; Pollock, J. S. Renal NOS activity, expression, and localization in male and female spontaneously hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2010, 298, R61-R69.
113. Umar, S.; Van der Laarse, A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol. Cell. Biochem., 2010, 333, 191-201.
114. Michel, T. Targeting and translocation of endothelial nitric oxide synthase. Braz. J. Med. Biol. Res., 1999, 32, 1361-1366.
115. Baylis, C. Nitric oxide deficiency in chronic kidney disease. Am. J. Physiol. Renal. Physiol., 2008, 294, F1-F9.
116. Pérez, T. I.; El Hafidi, M.; Zamora, G. J.; Infante, O.; Chavira, R.; Baños, G. Modulation of aortic vascular reactivity by sex hormones in a male rat model of metabolic syndrome. Life. Sci., 2007, 80, 2170-2180.
117. Vasudevan, H.; Nagareddy, P. R.; McNeill, J. H. Gonadectomy prevents endothelial dysfunction in fructose-fed male rats, a factor contributing to the development of hypertension. Am. J. Physiol. Heart. Circ. Physiol., 2006, 291, H3058-H3064.
118. Nava, E.; Farré, A. L.; Moreno, C.; Casado, S.; Moreau, P.; Cosentino, F.; Lüscher, T. F. Alterations to the nitric oxide pathway in the spontaneously hypertensive rat. J. Hypertens., 1998, 16, 609-615.
119. Neugarten, J.; Ding, Q.; Friedman, A.; Lei, J.; Silbiger, S. Sex hormones and renal nitric oxide synthases. J. Am. Soc. Nephrol., 1997, 8, 1240-1246.
120. Weiner, C. P.; Lizasoain, I.; Baylis, S. A.; Knowles, R. G.; Charles, I. G.; Moncada, S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc. Natl. Acad. Sci. USA, 1994, 91, 5212-5216.
121. Duncan, A. C.; Petrie, J. R.; Brosnan, M. J.; Devlin, A.; M.; Bass, R. A.; Charnock, D. S.; Connell J. M.; Dominiczak, A. F.; Lumsden, M. A. Is estradiol cardioprotection a nitric oxidemediated effect? Hum. Reprod., 2002, 17, 1918-1924.
122. Kim, K. H.; Moriarty, K.; Bender, J. R. Vascular cell signaling by membrane estrogen receptors., 2008, 73, 864-869.
123. Li, L.; Haynes, M. P.; Bender, J. R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc. Natl. Acad. Sci., 2003, 100, 4807-4912.
124. Huang, A.; Sun, D.; Koller, A.; Kaley, G. 17beta-estradiol restores endothelial nitric oxide release to shear stress in arterioles of male hypertensive rats. Circulation, 2000, 101, 94-100.
125. Enkhjargal, B.; Hashimoto, M.; Kinoshita, H.; Sakai, Y. Characteristics of contractile activity in the renal artery of ovariectomized rats. J. Smooth. Muscle. Res., 2008, 44, 17-28.
126. Pérez, T. I.; El Hafidi, M.; Infante, O.; Baños, G. Effects of sex hormone levels on aortic vascular reactivity and variables associated with the metabolic syndrome in sucrose-fed female rats. Can. J. Physiol. Pharmacol., 2008, 86, 25-35.
127. Kleinert, H.; Wallerath, T.; Euchenhofer, C.; Ihrig, B.; I.; Li, H.; Förstermann, U. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension., 1998, 31, 582-588.
128. Pfeilschifter, J.; Eberhardt, W.; Huwiler, A. Nitric oxide and mechanisms of redox signaling. J. Am. Soc. Nephrol., 2003, 14, S237-S240.
129. Mendelsohn, M. E. Estrogen actions in the cardiovascular system. Climacteric, 2009, 12, 18-21.
130. Brunini, T. M.; Moss, M. B.; Siqueira, M. A.; Santos, S. F.; Lugon, J. R.; Mendes, A. C. Nitric oxide, malnutrition and chronic renal failure. Cardiovasc. Hematol. Agents. Med. Chem., 2007, 5, 155-161.
131. Singh, R.; Pervin, S.; Shryne, J.; Gorski, R.; Chaudhuri, G. Castration increases and androgens decrease nitric oxide synthase activity in the brain: physiologic implications. Proc. Natl. Acad. Sci. USA, 2000, 97, 3672-3677.
132. Weiner, C. P.; Lizasoain, I.; Baylis, S. A.; Knowles, R. G.; Charles, I. G.; Moncada, S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc. Natl. Acad. Sci. USA, 1994, 91, 5212-5216.
133. Wynne, F. L.; Khalil, R. A. Testosterone and coronary vascular tone: implications in coronary artery disease. J. Endocrinol. Invest., 2003, 26, 81-86.
134. Simoncini, T.; Mannella, P.; Fornari, L.; Varone, G.; Caruso, A.; Genazzani, A. R. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology, 2003, 144, 3449-3455.
135. Tayebjee, M. H.; MacFadyen, R. J.; Lip, G. Y. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? J. Hypertens., 2003, 21, 2211-2218.
136. Zatz, R.; Meyer, T.; Rennket, H.; Brenner, B. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc. Natl. Acad. Sci., 1985, 82, 5963-5967.
137. Hosstetter, T. H, Troy, J. L.; Brenner, B. H. Glomerular hemodynamics in experimental diabetes mellitus. Kidney. Int., 1981, 19, 410-415.
138. Brenner, B. M.; Anderson, S. The interrelationships among filtration surface area, blood pressure, and chronic renal disease. J. Cardiovasc. Pharmacol., 1992, 19, S1-S7.
139. Tsilibary, E. C. Microvascular basement membranes in diabetes mellitus. J. Pathol., 2003, 200, 537-546.
140. Neugarten, J.; Medve, I.; Lei, J.; Silbiger, S. R. Estradiol suppresses mesangial cell type I collagen synthesis via activation of the MAP kinase cascade. Am. J. Physiol., 1999, 277, F875-F881.
141. Dixon, A.; Maric, C. 17beta-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling. Am. J. Physiol. Renal. Physiol., 2007, 293, F1678-F1690.
142. Hocevar, B. A.; Brown, T. L.; Howe, P. H. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. Embo. J., 1999, 18, 1345-1356.
143. Chen, S.; Jim, B.; Ziyadeh, F. N. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin. Nephrol., 2003, 23, 532-543.
144. Negulescu, O.; Bognar, I.; Lei, J.; Devarajan, P.; Silbiger, S.; Neugarten, J. Estradiol reverses TGF-beta1-induced mesangial cell apoptosis by a casein kinase 2-dependent mechanism. Kidney. Int., 2002, 62, 1989-1998.
145. Singh, R.; Choubey, D.; Chen, J.; Leehey, D.; J. Inhibition of intracellular angiotensin II formation blocks high glucose effect on mesangial matrix. Regul. Pept., 2009, 158, 103-109.
146. Maric, C.; Sandberg, K.; Hinojosa, L. C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. J. Am. Soc. Nephrol., 2004, 15, 1546-1556.
147. Mankhey, R. W.; Wells, C. C.; Bhatti, F.; Maric, C. 17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292, R769-R777.
148. Nielsen, C. B.; Flyvbjerg, A.; Bruun, J. M.; Forman, A.; Wogensen, L.; Thomsen, K. Decreases in renal functional reserve and proximal tubular fluid output in conscious oophorectomized rats: normalization with sex hormone substitution. J. Am. Soc. Nephrol., 2003, 14, 3102-3110.
149. Elliot, S. J.; Karl, M.; Berho, M.; Potier, M.; Zheng, F.; Leclercq, B.; Striker, G. E.; Striker, L. J. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am. J. Pathol., 2003, 162, 1441-1448.
150. Verzola, D.; Gandolfo, M. T.; Salvatore, F.; Villaggio, B.; Gianiorio, F.; Traverso, P.; Deferrari, G.; Garibotto, G. Testosterone promotes apoptotic damage in human renal tubular cells. Kidney. Int., 2004, 65, 1252-1261.
151. Metcalfe, P. D.; Leslie, J. A.; Campbell, M. T.; Meldrum, D. R.; Hile, K. L.; Meldrum, K. K. Testosterone exacerbates obstructive renal injury by stimulating TNF-alpha production and increasing proapoptotic and profibrotic signaling. Am. J. Physiol. Endocrinol. Metab., 2008, 294, E435-E443.
152. Elliot, S. J.; Berho, M.; Korach, K.; Doublier, S.; Lupia, E.; Striker, G. E.; Karl, M. Gender-specific effects of endogenous testosterone: female alpha-estrogen receptor-deficient C57Bl/6J mice develop glomerulosclerosis. Kidney. Int., 2007, 72, 464-472.
153. Lombet, J. R.; Adler, S. G.; Anderson, P. S.; Nast, C. C.; Olsen, D. R.; Glassock, R. J. Sex vulnerability in the subtotal nephrectomy model of glomerulosclerosis in the rat. J. Lab. Clin. Med., 1989, 114, 66-74.
154. Kwan, G.; Neugarten, J.; Sherman, M.; Ding, Q.; Fotadar, U.; Lei, J.; Silbiger, S. Effects of sex hormones on mesangial cell proliferation and collagen synthesis. Kidney. Int., 1996, 50, 1173-1179.
155. Baylis, C. Changes in renal hemodynamics and structure in the aging kidney; sexual dimorphism and the nitric oxide system. Exp. Gerontol., 2005, 40, 271-278.
156. Karagiannis, A.; Harsoulis, F. Gonadal dysfunction in systemic diseases. Eur. J. Endocrinol., 2005, 152, 501-513.
157. Schmidt, A.; Luger, A.; Hörl, W. H. Sexual hormone abnormalities in male patients with renal failure. Nephrol. Dial. Transplant., 2002, 17, 368-371.
158. Xu, Q.; Wells, C. C.; Garman, J. H.; Asico, L.; Escano, C. S.; Maric, C. Imbalance in sex hormone levels exacerbates diabetic renal disease. Hypertension, 2008, 51, 1218-1224.
159. El Hafidi, M.; Pérez, T, I.; Carrillo, S.; Cardoso, G.; Zamora, J.; Chavira, R.; Baños, G. Effect of sex hormones on non-esterified fatty acids, intra-abdominal fat accumulation, and hypertension induced by sucrose diet in male rats. Clin. Exp. Hypertens., 2006, 28, 669-681.